Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

Vertex said it has established a U.S. wholesale acquisition cost of $15.50 per 50 milligram pill for Journavx. Shares of the company rose nearly 4% in extended trading.

Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors By Nick Paul Taylor Dec 19, 2024 7:41am Vertex Pharmaceuticals pain drug clinical trial data Clinical Data ...

The New York Times will take down Vertex on Aug. 29. By Everdeen Mason My favorite part of this job is creating new things. I love the feeling of laboring with a group of kindred spirits to make ...

Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

Vertex disputes critics’ allegations of ‘scandalous’ drug pricing By Jonathan Saltzman Globe Staff,Updated April 11, 2024, 6:45 p.m.